This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Piatt, J. P. Articles by Bergeson, P. S. Search for Related Content PubMed PubMed Citation Articles by Piatt, J. P. Articles by Bergeson, P. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB HEXAMETHYL-P-ROSANILINE CHLORIDE Medline Plus Health Information Tongue Disorders Yeast Infections Social Bookmarking                         What's this?

Gentian Violet Toxicity

Department of Ambulatory Pediatrics Phoenix Children's Hospital Phoenix, Arizona

Paul S. Bergeson, M.D.

Department of Ambulatory Pediatrics Phoenix Children's Hospital Phoenix, Arizona

Currently, the use of 1 % and 2 % aqueous solutions of gentian violet (GV) is an acceptable treatment of thrush in infants. GV is generally considered efficacious; in fact, one study found GV superior to nystatin in treating thrush in infants. ¹ Oral nystatin is usually prescribed as the first-line drug for this infection, while GV is commonly reserved for nystatin failures. Although GV is widely regarded as an essentially harmless medication, we present a case of GV toxicity and review the literature on this subject.

Clinical Pediatrics, Vol. 31, No. 12, 756-757 (1992)
DOI: 10.1177/000992289203101212


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Baca, C. Drexler, and E. Cullen Obstructive Laryngotracheitis Secondary to Gentian Violet Exposure Clinical Pediatrics, April 1, 2001; 40(4): 233 - 235. [PDF]